Intermediate Risk Prostate Cancer
8
1
2
2
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
25.0%
2 terminated out of 8 trials
50.0%
-36.5% vs benchmark
0%
0 trials in Phase 3/4
100%
2 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (8)
Androgen-responsive POSLUMA-guided Intra-prostatic Boost
The PRECISION Study: 3 Fractions of Prostate SBRT and RayPilot HypoCath Image Guidance
VAccination in Early and ADvanced Prostate caNCEr
Spot-Scanning Based Hypofractionated Proton Therapy for Low and Intermediate Risk Prostate Cancer
Neoadjuvant ADT with TULSA in the Treatment of Intermediate Risk Prostate Cancer
Enzalutamide + External Beam Rt For Prostate
PROspective Multicenter Observational Study on Elective Pelvic Nodes Irradiation.
Assessment of New Radiation Oncology Technologies and Treatments